

IX International Conference: Complex Treatment of Plasma Cell Dyscrasias in 2020

This important and up-to-date 1-day conference has been organized by Professor Artur Jurczyszyn of the Jagiellonian University Medical College in Krakow, Poland.

The conference will be opened by Professor Artur Jurczyszyn and Professor Nikhil Munshi of the Harvard Medical School in Boston.

Session I will be chaired by Professors Aleksander B. Skotnicki, Grzegorz Helbig, and Jan Maciej Zaucha.

The Session will be opened by Professor David H. Vesole, John Theurer Cancer Center, Hackensack University Medical Center, New Jersey, USA, on the Best Therapy for Newly Diagnosed Patients with Multiple Myeloma in 2020. Dr. Vesole has had a great deal of experience with the diagnosis and management of multiple myeloma. He has been a leader in the field for decades.

Professor Thierry Facon from the University of Lille, Lille, France, and a member of the French Myeloma Group will describe new treatment options for the newly diagnosed multiple myeloma patient. This is an important part of multiple myeloma therapy because the physician and the patient must make a decision concerning the role of autologous stem cell transplantation in this situation. Professor Facon and his colleagues have made many important observations and advancements in the treatment of the newly diagnosed myeloma patient over the past quarter century.

Professor Michael Delforge of the Department of Hematology and Leuven Cancer Institute, Leuven, Belgium, will follow with Therapy of the Multiple Myeloma Patient who has Relapsed or is Refractory to Therapy. This is an important aspect because we have a large number of useful therapeutic drugs for these patients, but it is a challenge to select which regimen would be best for a given patient. Professor Delforge has had a good deal of experience in the field and will provide guidance concerning the best regimen for the patient. Although many agents are available for therapy, patients often become refractory and management is a major challenge. Many patients still die of multiple myeloma.

CAR-T Cell therapy is a very interesting approach and oftentimes produces spectacular results, but relapse often occurs following therapy. This will be presented by Professor Parameswaran Hari from the Cancer Center of Froedtert Hospital, Milwaukee, Wisconsin, USA.

Professor Nikhil Munshi will discuss new immunotherapies as well as vaccine approaches for multiple myeloma. This is a field in which Dr. Munshi has been an international leader.

Session II will be chaired by Professors Jerzy Holowiecki, Sebastian Grosicki, and Boguslaw Machalinski.

Professor Evangelos Terpos of the National and Kapodistrian University of Athens, Athens, Greece, will present up-to-date data and information concerning imaging and will concentrate on bone disease in multiple myeloma. He is a well-known expert in the field and has written many papers on the subject.

Professor Jorge J. Castillo of Dana Farber Cancer Institute, Boston, MA, will discuss the New Developments in Therapy of Waldenstrom's Macroglobulinemia. Although this is a rare disease, it is important to learn about newer aspects in diagnosis and therapy. Despite the introduction of newer agents, management of patients with this disease present many challenges. Dr. Castillo has had a great deal of experience in the field and will enlighten the participants.

Professor Artur Jurczyszyn, the organizer of the conference, will talk about the diagnosis and management of plasma cell leukemia. This rare complication is extremely serious from the patient's standpoint and, despite the novel agents, it is still a dangerous disorder.

The final topic will be on Amyloidosis and POEMS Syndrome. The emphasis will be on the current treatment of the patient. This will be presented by Professor Shaji Kumar, an experienced Mayo Clinic consultant in the field of the dysproteinemias. Amyloidosis is particularly challenging in that there are a number of different types of amyloidosis that require different therapeutic approaches. There is no one better than Professor Kumar in presenting the options of therapy. POEMS Syndrome is even more rare than amyloidosis and must be recognized as it is very easy to overlook. Patients who are appropriately treated may enjoy a long life.

This conference will update the participants on the diagnosis, treatment and management of patients with multiple myeloma, CART Cell Therapy, diagnosis and management of myeloma bone disease as well as important presentations on Waldenstrom's Macroglobulinemia, amyloidosis, plasma cell leukemia and POEMS Syndrome by international experts.


ROBERT A. KYLE, M.D.

Robert A. Kyle, MD, MACP
Professor of Medicine,
Laboratory Medicine & Pathology
Mayo Clinic